


# Discover our *in vitro* T cell cytotoxicity models

Our assay employs PBMC-isolated human T cells as effectors, which directly engage with cells expressing your target of interest. We use historical data and our extensive expertise to tailor the assay format to benefit your research.

Target cells can consist of primary cells, cell lines or our Cell Line Development service can engineer cells to express your chosen target. T cell and target cell co-cultures will be assessed with all necessary controls and compared directly to your therapeutic candidate. Our assays can be adapted for kinetic impedance, flow cytometry and cytokine readouts. Boost your data package by adopting our assay to answer your questions.

## Assay set up



# The model is a medium throughput, flexible assay set-up ideal for MoA assessment of:

- Checkpoint inhibitors
- Co-stimulation agonists
- Bispecifics / T cell engagers
- Modulators of T cell signalling and/or function
- Kinase inhibitors
- Immunometabolism modulators

We can adapt the set up to assess cytotoxicity and cytokine release of engineered immune cell therapies. e.g. CAR-T cells.

## Why choose RoukenBio's *in vitro* T cell cytotoxicity models?



### Target cells

A large repository of commercial target cell lines are available. We can also provide custom target cell line development expertise to further boost your research.



### Access to cryopreserved banks of human T cell donors

To maximise assay success, we perform optimisation of effector to target ratios and seeding densities prior to assay set up.



### High content assay readouts

Phenotype and function are measured using a combination of multi-parameter flow cytometry, kinetic (or end point) cytotoxicity measurements and multiplex cytokine readouts. 96-well plate formats provide a medium throughput assay with up to 720 testing wells per run.

**Download** our T cell cytotoxicity slide deck to learn more.



## RoukenBio - The CRO redefined

Backed by our brilliant minds, we have turned the traditional CRO model on its head, by fostering a collaborative and personalised approach. Our mission is simple:

**Solve problems. Deliver quality data. Propel your drug discovery breakthroughs.**

United by a passion to make sense of complexities and overcome challenges, we apply our specialised knowledge to big-picture thinking. We will explore every option to deliver over and above for your project.

We are thought leaders with a deep understanding of immunology, bioassays, molecular biology and a track record of groundbreaking discoveries and novel cell-based tools.